ECCT Therapy

31/03/2026

A Turning Point in Intrahepatic Cholangiocarcinoma Bile Duct Cancer: From Progression to Disease Control with ECCT

Rachel Lee Li Ken, a Malaysiian, 51-year-old woman, was diagnosed in May 2025 with intrahepatic cholangiocarcinoma bile duct cancer after elevated tumour markers were found during a routine health screening. Further evaluation revealed a 7–8 cm liver tumour with additional nodules and lymph node involvement, indicating a significant disease burden from the beginning. She started chemotherapy and immunotherapy on 23 June 2025, and early scans showed some tumour shrinkage. However, at the same time, her tumour marker CA 19-9 rose rapidly from 49 to 927, and then to 1306 within weeks, suggesting that despite imaging improvement, the disease remained active. During this period, she also experienced weight loss (55.8 kg to 52.6 kg), mild fatigue, hair thinning, and transient hyperthyroidism.

ECCT was introduced on 20 July 2025 alongside her ongoing treatment, and from that point a clear shift was observed. Her tumour marker, which had been rising aggressively, began to decline steadily, from 1306.6 to 573.7 by November, to 21.1 in December, and to 16.4 in January 2026, returning to normal range. At the same time, imaging continued to improve, with further reduction in tumour size (approximately 7.8 cm to 7.0 cm), decreased metabolic activity, and regression of lymph node involvement. With this level of control, she was able to undergo successful laparoscopic liver resection (segments 5, 6, 7) and lymph node removal in December 2025.

Follow-up imaging in January 2026 showed no new metastatic disease, stable or reduced lymph nodes, no ascites, and no signs of active progression, with only a small indeterminate area requiring monitoring. Her blood parameters also demonstrated recovery and stability, with haemoglobin improving from 10.5 post-surgery to 12.8, liver enzymes normalising after temporary elevation, albumin remaining stable (41–47), and renal function preserved throughout. Clinically, she maintained good appetite and energy, continued daily activities including walking and Qi Gong, and recovered quickly after surgery, being discharged within five days, without significant ongoing side effects.

Her treatment journey combined chemotherapy and immunotherapy (June–October 2025), continuous ECCT from July 2025 onward with progressive optimisation, surgical resection in December 2025, and ongoing maintenance therapy with ECCT. As of her latest follow-up, she remains clinically stable, with normal tumour markers, no evidence of disease progression, and preserved quality of life. Rachel’s case reflects a true turning point, from a phase of ongoing biological activity despite treatment, to sustained disease control.

https://www.ecct-asia.com/post/intrahepatic-cholangiocarcinoma-bile-duct-cancer-from-progression-to-control

30/03/2026

30/03/2026

29/03/2026

Journey of Recovery and Stability in Advanced Rectosigmoid Cancer with ECCT Support

When 53-year-old Juliana Asfalinda, Malaysia was first diagnosed with rectosigmoid adenocarcinoma in April 2025, her life changed almost overnight. What initially began as a tumour measuring 3.8 × 2.2 cm soon revealed itself to be more aggressive than expected, with invasion into surrounding tissues and spread to nearby lymph nodes (4 out of 11 positive).
She underwent surgery in May 2025 to remove the tumour. At that point, there was hope. However, due to a delay in starting chemotherapy, things quickly took a turn. Within just two months, she began experiencing persistent abdominal pain. At first, it seemed like something minor, “just gas,” she thought, but the discomfort worsened.
Further investigations in October 2025 confirmed what no patient wants to hear: the cancer had returned and spread. Scans showed active disease in the bowel, lymph nodes, and even nodules in the abdominal wall.

Before ECCT: Weak, In Pain, and Losing Weight
By the time Juliana started treatment again in October 2025, her condition had significantly declined.
She was dealing with constant abdominal pain, described as a pulling, tightening sensation, along with bloating, vomiting, and a severely reduced appetite. Eating became difficult, and she relied on liquid nutrition just to get through the day. She lost about 5 kg in a short period.
Physically, she was weak and lethargic, often needing to lie down during consultations. Even basic daily activities felt exhausting.

Starting Treatment: Combining Chemotherapy with ECCT
Determined to fight back, Juliana began chemotherapy (initially Xeloda, later Oxaliplatin-based regimens) on 6 October 2025. At the same time, she started ECCT on 10 October 2025.
The early phase was not easy. Like many patients undergoing chemotherapy, she experienced side effects, insomnia, poor appetite, cold sensitivity, and fatigue. There were also episodes of severe abdominal pain and weakness.
But gradually, something began to change.

Signs of Improvement: Tumour Markers and Scan Results
One of the clearest signs came from her tumour marker (CEA), which steadily decreased after starting treatment:
• From 21 (April 2025)
• Down to 10.7 in early October
• Further reduced to 9.4, then 6.4
• And eventually reaching 3.5 by December 2025
This consistent downward trend into near-normal levels suggested a meaningful reduction in tumour activity.
Follow-up CT scans in February 2026 brought more encouraging news. The previously suspicious thickening in the bowel area became less visible, and importantly, there were no new tumours detected. Existing nodules and lymph nodes remained stable, showing that the disease was under control rather than progressing.

Blood Tests and Internal Recovery
There were challenges along the way. Her liver function became affected, most likely due to chemotherapy, and she experienced episodes of low white blood cells and platelets.
However, with adjustments to her treatment (including adjusting ECCT regime to improve her liver, kidney and bone marrow, stopping Oxaliplatin and continuing Xeloda at a reduced dose), her condition stabilised. Liver function showed signs of improvement, and her kidney function remained normal throughout.

Feeling the Difference: Physical and Symptom Improvement
The biggest change wasn’t just in the numbers; it was how Juliana felt.
Over time, her symptoms began to fade:
• The abdominal pain and bloating resolved
• Her appetite improved
• Bowel movements returned to normal
• Back pain and gastric discomfort disappeared
By early 2026, she was no longer the weak, fatigued patient from months before. She was sitting upright, alert, and visibly stronger.
She shared that while chemotherapy still made her feel unwell for a few days after each cycle, she would recover much faster and felt that ECCT helped her bounce back more quickly.

Getting Her Life Back
Perhaps the most meaningful part of her recovery is what it allowed her to do.
Juliana was able to travel again. She drove herself on a trip to Penang, something that would have been unimaginable just a few months earlier. She resumed her daily routines, including fasting, and regained a sense of independence.
These are not just small milestones; they represent a return to normalcy and dignity in daily life.

Where She Is Today
As of the latest follow-up:
• Her disease remains stable on imaging
• Tumour markers are within normal range
• Liver function, while previously affected, is improving
• She remains physically well, active, and independent
There are ongoing considerations, including monitoring thyroid nodules and continued follow-up scans, but overall, her condition is stable and controlled.

A Journey of Measurable Progress
Juliana’s journey reflects more than just clinical improvement. It shows how a patient who started off weak, in pain, and facing disease progression can regain strength, stability, and quality of life.
With a combination of chemotherapy and ECCT, her case demonstrates:
• Reduction in tumour activity (CEA improvement)
• Stabilisation of disease on imaging
• Recovery of physical strength
• Improved tolerance to treatment
• Restoration of daily function and independence
Today, she is not just continuing treatment, she is living her life again.

https://www.ecct-asia.com/post/stability-in-advanced-rectosigmoid-cancer-with-ecct-support

29/03/2026

Stage 4 Prostate Cancer PSA Drop: Real Case Showing >99% Reduction After ECCT Integration

When this Malaysian, 39-year-old male was diagnosed in early October 2025, evaluation confirmed metastatic prostate adenocarcinoma with both nodal and extensive skeletal involvement. CT imaging demonstrated left iliac and para-aortic lymphadenopathy together with diffuse sclerotic and lytic bone lesions involving the pelvis and spine. PET-CT performed on 14 October 2025 confirmed PSMA-avid disease within the prostate, nodal metastases, and widespread skeletal involvement. Histopathology showed acinar adenocarcinoma with Gleason score 4+4 (Grade Group 4), consistent with high-risk disease biology.

At diagnosis, hix PSA was markedly elevated at 784 (October 2025), indicating a substantial systemic tumor burden. Systemic treatment was initiated with chemotherapy in combination with androgen deprivation (pamorelin) and androgen receptor pathway inhibition (enzalutamide). ECCT was incorporated into his treatment plan on 11 December 2025 as a non-invasive adjunct and continued alongside ongoing oncologic therapy.

Following this integration, PSA demonstrated a sustained and progressive decline, reaching 6.96 (6 January 2026), 4.87 (27 January 2026), 3.19 (24 February 2026), and ultimately 3.01 (24 March 2026). This represents a reduction of PSA Drop greater than 99% from baseline, with a consistent downward trajectory and no interval rise. In metastatic prostate cancer, sustained suppression of PSA over time is clinically significant and reflects continued control of tumor activity.

In parallel, hematologic parameters demonstrated recovery rather than treatment-related decline. Hemoglobin improved from 7.7 (4 November 2025) to 12.9 (24 March 2026), reflecting resolution of initial anemia. Platelet counts remained within acceptable ranges, and there was no evidence of clinically significant bone marrow suppression despite ongoing chemotherapy. White blood cell profiles remained stable without recurrent infection, suggesting preserved immune function during treatment. Biochemical trends further demonstrated maintenance of organ function.

Initial elevations in liver enzymes (ALP 386, ALT 116, AST 57 on 4 November 2025) showed progressive improvement over time, with ALP decreasing to 123, ALT to 15, and AST to 16 by March 2026. Renal function remained stable across serial measurements, with creatinine values consistently in the mid-50s and eGFR maintained above 120, indicating preserved renal function. Electrolytes remained within normal limits throughout.

Key Clinical Interpretation:
Tumor Activity: PSA reduced by more than 99%, showing sustained biochemical response
Hematologic Recovery: Hemoglobin normalized from anemia without marrow suppression
Liver Function: Significant improvement with normalization of ALT and AST
Renal Function: Remained stable and within normal limits
Overall: No evidence of treatment-limiting toxicity; systemic function preserved

Clinically, the patient maintained stable performance status without development of significant systemic symptoms. There was no progression to bone pain, functional decline, or treatment-limiting toxicity during this period. He continues systemic therapy with ongoing monitoring. While follow-up imaging has not yet been performed, the magnitude and consistency of PSA reduction, together with recovery of hematologic parameters and preservation of organ function, support sustained disease control at a biological level.

This case demonstrates that in metastatic prostate adenocarcinoma, meaningful treatment response can be reflected through sustained biochemical suppression alongside preserved systemic function. A >99% reduction in PSA, combined with normalization of hematologic and biochemical parameters, represents a clear shift toward biological control under active treatment. This is presented not as a claim of cure, but as objective documentation of response and maintained physiological stability within a structured, closely monitored therapeutic approach.

https://www.ecct-asia.com/post/stage-4-prostate-cancer-psa-drop-real-case-showing-99-reduction-after-ecct

29/03/2026

Stage 4 Prostate Cancer PSA Drop: Real Case Showing >99% Reduction After ECCT Integration

When this Malaysian, 39-year-old male was diagnosed in early October 2025, evaluation confirmed metastatic prostate adenocarcinoma with both nodal and extensive skeletal involvement. CT imaging demonstrated left iliac and para-aortic lymphadenopathy together with diffuse sclerotic and lytic bone lesions involving the pelvis and spine. PET-CT performed on 14 October 2025 confirmed PSMA-avid disease within the prostate, nodal metastases, and widespread skeletal involvement. Histopathology showed acinar adenocarcinoma with Gleason score 4+4 (Grade Group 4), consistent with high-risk disease biology.

At diagnosis, hix PSA was markedly elevated at 784 (October 2025), indicating a substantial systemic tumor burden. Systemic treatment was initiated with chemotherapy in combination with androgen deprivation (pamorelin) and androgen receptor pathway inhibition (enzalutamide). ECCT was incorporated into his treatment plan on 11 December 2025 as a non-invasive adjunct and continued alongside ongoing oncologic therapy.

Following this integration, PSA demonstrated a sustained and progressive decline, reaching 6.96 (6 January 2026), 4.87 (27 January 2026), 3.19 (24 February 2026), and ultimately 3.01 (24 March 2026). This represents a reduction of PSA Drop greater than 99% from baseline, with a consistent downward trajectory and no interval rise. In metastatic prostate cancer, sustained suppression of PSA over time is clinically significant and reflects continued control of tumor activity.

In parallel, hematologic parameters demonstrated recovery rather than treatment-related decline. Hemoglobin improved from 7.7 (4 November 2025) to 12.9 (24 March 2026), reflecting resolution of initial anemia. Platelet counts remained within acceptable ranges, and there was no evidence of clinically significant bone marrow suppression despite ongoing chemotherapy. White blood cell profiles remained stable without recurrent infection, suggesting preserved immune function during treatment. Biochemical trends further demonstrated maintenance of organ function.

Initial elevations in liver enzymes (ALP 386, ALT 116, AST 57 on 4 November 2025) showed progressive improvement over time, with ALP decreasing to 123, ALT to 15, and AST to 16 by March 2026. Renal function remained stable across serial measurements, with creatinine values consistently in the mid-50s and eGFR maintained above 120, indicating preserved renal function. Electrolytes remained within normal limits throughout.

Key Clinical Interpretation:
Tumor Activity: PSA reduced by more than 99%, showing sustained biochemical response
Hematologic Recovery: Hemoglobin normalized from anemia without marrow suppression
Liver Function: Significant improvement with normalization of ALT and AST
Renal Function: Remained stable and within normal limits
Overall: No evidence of treatment-limiting toxicity; systemic function preserved

Clinically, the patient maintained stable performance status without development of significant systemic symptoms. There was no progression to bone pain, functional decline, or treatment-limiting toxicity during this period. He continues systemic therapy with ongoing monitoring. While follow-up imaging has not yet been performed, the magnitude and consistency of PSA reduction, together with recovery of hematologic parameters and preservation of organ function, support sustained disease control at a biological level.

This case demonstrates that in metastatic prostate adenocarcinoma, meaningful treatment response can be reflected through sustained biochemical suppression alongside preserved systemic function. A >99% reduction in PSA, combined with normalization of hematologic and biochemical parameters, represents a clear shift toward biological control under active treatment. This is presented not as a claim of cure, but as objective documentation of response and maintained physiological stability within a structured, closely monitored therapeutic approach.

https://www.ecct-asia.com/post/stage-4-prostate-cancer-psa-drop-real-case-showing-99-reduction-after-ecct

27/03/2026

Want to lower your cancer risk❓

Start with something simple — your sleep 😪

Most people focus on what they eat, what supplements they take, or what they do…

But very few realise
your body repairs itself while you sleep

When you stay up late regularly,
your hormones can become unbalanced,
your immune system weakens,
and your body doesn’t get enough time to repair itself 🔧

And the scary part❓
You might still feel “fine” — until one day, you’re not

Small habit. Big impact.

🔴 Sleep before midnight
🔴 Keep a consistent sleep routine
🔴 Give your body the rest it needs

Because prevention doesn’t start when there’s a problem
It starts with what you do every day ✨

But beyond daily habits,
there are also non-invasive ways to support your body,
like ECCT — designed to help regulate abnormal cell activity
without harming normal cells

Taking care of your health
is not just one action,
it’s a combination of the right habits + the right support 💪

📩 If you’d like to learn more about ECCT or how to better support your health, feel free to message us

27/03/2026

2015年，他被医生告知：
第四期前列腺癌，而且已经扩散到骨头🦴

那一刻，其实他心里很清楚
因为母亲和嫂子，都是因为癌症离开的…

一开始，他照着医生建议做激素治疗
但身体很快撑不住，副作用一点一点累积上来😢

后来，他做了一个决定
那就是换一种方式试试看

他开始接触ECCT，
同时也把生活整个调整过来：
每天喝胡萝卜汁、改成素食、戒糖🍬

几个月后，变化慢慢出现了‼️

PSA从很高的数值，一点一点往下降
复查的时候，骨头上的黑斑也开始减少

最特别的是
他整个人的状态，反而越来越像“正常人”
可以走动、可以生活，不再只是一个病人的样子

这不是一夜逆转，
而是慢慢坚持出来的结果

而他后来也分享，
ECCT对他来说，更像是一种长期辅助的支持方式，
在不增加身体负担的情况下，
陪着他一起对抗这个病💪

有时候，治疗不只是单一选择，
而是找到适合自己、能走得长远的方法

📩 想了解ECCT是怎样帮助他的，可以直接dm我哦

#前列腺癌 #癌症故事 #马来西亚 #辅助治疗 #晚期癌症 #第四期 #骨转移 #癌症科普

27/03/2026

Want to lower your cancer risk❓

Start with something simple — your sleep 😪

Most people focus on what they eat, what supplements they take, or what they do…

But very few realise
your body repairs itself while you sleep

When you stay up late regularly,
your hormones can become unbalanced,
your immune system weakens,
and your body doesn’t get enough time to repair itself 🔧

And the scary part❓
You might still feel “fine” — until one day, you’re not

Small habit. Big impact.

🔴 Sleep before midnight
🔴 Keep a consistent sleep routine
🔴 Give your body the rest it needs

Because prevention doesn’t start when there’s a problem
It starts with what you do every day ✨

But beyond daily habits,
there are also non-invasive ways to support your body,
like ECCT — designed to help regulate abnormal cell activity
without harming normal cells

Taking care of your health
is not just one action,
it’s a combination of the right habits + the right support 💪

📩 If you’d like to learn more about ECCT or how to better support your health, feel free to message us

27/03/2026

第四期前列腺癌➕骨转移，他的复查结果出现明显改善

2015年，他被医生告知：
第四期前列腺癌，而且已经扩散到骨头🦴

那一刻，其实他心里很清楚
因为母亲和嫂子，都是因为癌症离开的…

一开始，他照着医生建议做激素治疗
但身体很快撑不住，副作用一点一点累积上来😢

后来，他做了一个决定
那就是换一种方式试试看

他开始接触ECCT，
同时也把生活整个调整过来：
每天喝胡萝卜汁、改成素食、戒糖🍬

几个月后，变化慢慢出现了‼️

PSA从很高的数值，一点一点往下降
复查的时候，骨头上的黑斑也开始减少

最特别的是
他整个人的状态，反而越来越像“正常人”
可以走动、可以生活，不再只是一个病人的样子

这不是一夜逆转，
而是慢慢坚持出来的结果

而他后来也分享，
ECCT对他来说，更像是一种长期辅助的支持方式，
在不增加身体负担的情况下，
陪着他一起对抗这个病💪

有时候，治疗不只是单一选择，
而是找到适合自己、能走得长远的方法

📩 想了解ECCT是怎样帮助他的，可以直接dm我哦

#前列腺癌 #癌症故事 #马来西亚 #辅助治疗 晚期癌症 ecct疗法 第四期 骨转移 癌症科普

24/03/2026

No pain doesn’t mean no problem.

We often associate illness with pain, discomfort, or obvious symptoms.
But the truth is, many serious conditions don’t start that way.

They begin quietly.
No pain. No warning. No clear signs.⚠️

And that’s what makes them dangerous‼️

Because when nothing feels wrong,
we naturally assume everything is fine.

We postpone check-ups.
We ignore small changes in our body.
We tell ourselves, “I’m still okay.”

But sometimes, “okay” is only what it looks like on the surface.

Behind the scenes, changes may already be happening.

By the time symptoms finally appear,
the condition may no longer be at an early stage.

And that’s when treatment becomes harder,
more stressful, and more overwhelming.

The most dangerous moment
isn’t when you’re sick.

It’s when you think you’re completely fine…
and choose to do nothing.

Health isn’t just about how you feel today.
It’s about what could be happening silently inside your body.

That’s why early screening, regular check-ups,
and paying attention to your body matter so much.

Not because something is wrong,
but because you want to make sure everything stays right.

Taking care of your health isn’t about fear.
It’s responsibility. It’s awareness. It’s self-respect.

Don’t wait for pain to remind you.
Don’t wait for symptoms to convince you.

The best time to take action
is when you still feel okay.

Because prevention is always better than cure.

Take care of yourself —
not just when you feel unwell,
but especially when you don’t. 🤍